Approval BlogMedical CommunicationsOncology Updates Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma
Approval BlogMedical CommunicationsOncology Updates Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Approval BlogMedical CommunicationsOncology Updates Blinatumomab for Patients with MRD-positive B-cell Precursor ALL
Approval BlogMedical CommunicationsOncology Updates Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML
Medical CommunicationsOncology Updates Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
Medical CommunicationsOncology Updates Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer
Approval BlogMedical CommunicationsOncology Updates Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer
Approval BlogMedical CommunicationsOncology Updates Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer
Approval BlogMedical CommunicationsOncology Updates Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors
Approval BlogMedical CommunicationsOncology Updates Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer